140 related articles for article (PubMed ID: 24608924)
1. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
Karakhanova S; Mosl B; Harig S; von Ahn K; Fritz J; Schmidt J; Jäger D; Werner J; Bazhin AV
Int J Mol Sci; 2014 Mar; 15(3):4104-25. PubMed ID: 24608924
[TBL] [Abstract][Full Text] [Related]
2. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Schmidt J; Jäger D; Hoffmann K; Büchler MW; Märten A
J Immunother; 2007 Jan; 30(1):108-15. PubMed ID: 17198089
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Ryschich E; Märten A
J Immunother; 2008 Sep; 31(7):599-606. PubMed ID: 18600184
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Karakhanova S; Ryschich E; Mosl B; Harig S; Jäger D; Schmidt J; Hartwig W; Werner J; Bazhin AV
Br J Cancer; 2015 Mar; 112(6):1027-36. PubMed ID: 25742476
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
7. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Nukui Y; Picozzi VJ; Traverso LW
Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
[TBL] [Abstract][Full Text] [Related]
8. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
9. Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].
Hoffmann K; Marten A; Lindel K; Fritz S; Jager D; Buchler MW; Schmidt J
BMC Cancer; 2006 May; 6():128. PubMed ID: 16686958
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).
Schmidt J; Patrut EM; Ma J; Jäger D; Knaebel HP; Büchler MW; Märten A
Cancer Immunol Immunother; 2006 Nov; 55(11):1396-405. PubMed ID: 16485127
[TBL] [Abstract][Full Text] [Related]
12. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
Snady H; Bruckner H; Cooperman A; Paradiso J; Kiefer L
Cancer; 2000 Jul; 89(2):314-27. PubMed ID: 10918161
[TBL] [Abstract][Full Text] [Related]
13. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
16. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: a Phase II pilot study.
Jensen EH; Armstrong L; Lee C; Tuttle TM; Vickers SM; Sielaff T; Greeno EW
HPB (Oxford); 2014 Feb; 16(2):131-9. PubMed ID: 23509924
[TBL] [Abstract][Full Text] [Related]
18. In vitro immunomodulatory properties of gemcitabine alone and in combination with interferon-alpha.
Fritz J; Karakhanova S; Brecht R; Nachtigall I; Werner J; Bazhin AV
Immunol Lett; 2015 Nov; 168(1):111-9. PubMed ID: 26450014
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
Wagener DJ; Wils JA; Kok TC; Planting A; Couvreur ML; Baron B
Eur J Cancer; 2002 Mar; 38(5):648-53. PubMed ID: 11916546
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
